Method of treating weight loss using creatine

• US 20030013767A1
• Filed: 07/11/2002
• Published: 01/16/2003
• Est. Priority Date: 07/13/2001
• Status: Abandoned Application

• Current Assignee: Samuel Bessman
• Original Assignee: Samuel Bessman
• Inventors: Bessman, Samuel
• Application Number:
  US10/193,853
• Publication Number:
  US 20030013767A1
• Time in Patent Office: Days
• US Class Current: 514/565
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00

Abstract

A method of using a creatine compound to treat muscle loss associated with liver and kidney diseases. In preferred embodiments, creatine monohydrate is administered by dialysis. The method can be extended to other diseases or conditions associated with muscle loss. Also provided is a composition comprising a dialysis fluid containing a creatine compound.

Claims

1. A method of treating muscle loss in a subject suffering muscle loss from reduced production of endogenous creatine, comprising administering an effective amount of a creatine compound.

2. The method of claim 1 in which the subject is

a subject with kidney disease,

a subject with liver disease,

a subject suffering from anorexia nervosa,

a subject with chronic gastrointestinal disease,

a subject with severe wounds that interfere with oral intake of food,

a parenterally fed subject, or

a failure-to-thrive infant.

3. The method of claim 2 in which the subject is a subject with kidney disease or a subject with liver disease.

4. The method of claim 2 in which the subject is a vegetarian with mild kidney disease.

5. The method of claim 2 in which the subject is a vegetarian with mild liver disease.

6. The method of claim 1 in which the creatine compound is creatine, a pharmaceutically acceptable creatine analog, a pharmaceutically acceptable creatine precursor, a pharmaceutically acceptable creatine pro-drug, or biologically active salts thereof.

7. The method of claim 1 in which the creatine compound is creatine monohydrate, creatine phosphate, cyclocreatine, guanidoacetic acid, or hydrosoluble organic salts of creatine.

8. The method of claim 7 in which the creatine compound is creatine monohydrate.

9. The method of claim 1 in which the creatine compound is administered by dialysis.

10. The method of claim 9 in which the creatine compound is creatine monohydrate.

11. The method of claim 10 in which creatine monohydrate has a concentration of up to about 1.5 g/100 ml of dialysis fluid.

12. The method of claim 11 in which creatine monohydrate has a concentration of about 1.5 g/100 ml of dialysis fluid.

15. The dialysis fluid of claim 14 in which the creatine compound is creatine, a pharmaceutically acceptable creatine analog, a pharmaceutically acceptable creatine precursor, a pharmaceutically acceptable creatine pro-drug, or biologically active salts thereof.

16. The dialysis fluid of claim 14 in which the creatine compound is creatine monohydrate, creatine phosphate, cyclocreatine, guanidoacetic acid, or hydrosoluble organic salts of creatine.

17. The dialysis fluid of claim 16 in which the creatine compound is creatine monohydrate.

18. The dialysis fluid of claim 17 in which creatine monohydrate has a concentration of up to about 1.5 g/100 ml of fluid.

19. The dialysis fluid of claim 18 in which creatine monohydrate has a concentration of about 1.5 g/100 ml of fluid.

20. The dialysis fluid of claim 14 in which the dialysis fluid is a hemodialysis fluid.

21. The dialysis fluid of claim 14 in which the dialysis fluid is a peritoneal dialysis fluid.

13. A method of counteracting muscle loss associated with diseases of liver and kidney, comprising administering an effective amount of creatine monohydrate to a subject suffering such muscle loss, the creatine monohydrate administered by dialyzing the subject with a dialysis fluid containing creatine monohydrate.

14. A dialysis fluid for treating muscle loss, the dialysis fluid containing a creatine compound.

22. A dialysis fluid for treating muscle loss associated with diseases of liver and kidney, the dialysis fluid containing creatine monohydrate.